ZYBERNO
Stock Report
Updated Aug 30, 2026

FORTE BIOSCIENCES, INC. (FBRX)

Healthcare • NASDAQ

$76.99

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
FORTE BIOSCIENCES, INC. (FBRX) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-94.8%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.01x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-931.9%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

FORTE BIOSCIENCES, INC. (FBRX) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, FBRX generated -$59.35M in Owner Earnings. Capital was deployed as follows: $55.00K invested in capital expenditures. Reinvestment rate: -0.1%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:76.99
Market Cap:$1.58B

Valuation Multiples (2)

P/B Ratio:8.58x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$1.38B

Price Action & Momentum (1)

% of 52-Week High:99.7%
B. Profitability Assessment

Return Metrics (5)

ROA:-77.7%
Reinvestment Rate:-0.1%
Fundamental Growth Rate (g):0.7%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$5.98
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:96.6%
Latest Earnings Filed:2026-08-12
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:10.01x
Quick Ratio:10.01x
Cash Ratio:9.78x

Leverage Analysis (3)

Debt To Equity Ttm:0.01x
Debt-to-Equity Ratio:0.01x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-26.02x
Times Interest Earned:-26.02

Capital Structure (4)

Working Capital:182,814,000.00
Cash And Cash Equivalents:198,500,000.00
Long Term Debt:$1.66M
Net Debt:-$196.84M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$90.00M

Bottom Line Performance (3)

-$87.94M
Income Before Tax:-$62.51M
Ebitda Ttm:-89,926,000.00

Operating Expenses (5)

Operating Expenses:89,996,000.00
R And D Expense:79,142,000.00
Sga Expense:10,254,000.00
Income Tax Expense:$193.00K
Interest Expense:2,715,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$205.74M
Current Assets:$203.10M
Ppe Net:90,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:21,949,000.00
Current Liabilities:20,289,000.00
Long Term Debt:$1.66M
Short Term Debt:$0.00

Equity & Capital (3)

Equity:$183.79M
Retained Earnings:-$268.84M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:14,010,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:3,666,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$59.34M-$59.39M

Investment Activities (2)

Investing Cash Flow:$0.00
Capital Expenditures Ttm:55,000.00

Financing Activities (3)

Financing Cash Flow:$74.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:8,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:70,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-4.59
-$4.59
Earnings Per Share Ttm:-$4.29

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$2.48

Book Value & Capital (2)

Book Value Per Share:$8.97
Cash Per Share:9.69

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$59.35M

Damodaran Growth Analysis (2)

Reinvestment Rate:-0.1%
Fundamental Growth Rate (g):0.7%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):24.3%
C. Company Profile & Context

Corporate Information (6)

Symbol:FBRX
Company Name:FORTE BIOSCIENCES, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:high
Volume Category:N/A

Share Structure (3)

Shares Outstanding:20.48M
Shares Outstanding Basic:20.48M
Shares Outstanding Diluted:21.05M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-30 22:04:20 UTC
Data Timestamp:2026-08-18T01:15:18.124479
Scroll to Top